Avantor Stock Plunges as Q3 Earnings Miss Estimates, Revenues Down Y/Y

Avantor (AVTR) reported a significant Q3 2025 earnings and revenue miss, with adjusted EPS of $0.22 down 15.4% year-over-year and revenue of $1.62 billion declining 5.3%, leading to a 23.2% stock plunge. The underperformance was attributed to softer customer activity and competitive pressures in Laboratory Solutions, alongside self-inflicted operational challenges in Bioscience Production. Consequently, the company lowered its full-year 2025 adjusted EPS guidance to $0.88-$0.92 and organic revenue growth to negative 3.5% to negative 2.5%, while outlining a multi-year 'Avantor Revival' plan focused on a $400 million cost-transformation program and operational improvements.

Analysis

Avantor (AVTR) reported a dismal Q3 2025, with adjusted EPS of $0.22 missing estimates by 4.4% and declining 15.4% year-over-year, while revenue of $1.62 billion fell 5.3% and missed consensus by 1.6%. This underperformance, including a GAAP loss per share of $1.04, triggered a significant 23.2% stock plunge.

Both core segments contributed to the weakness; Laboratory Solutions' organic sales dropped 4.9% due to softer customer activity and competitive pressures, and Bioscience Production's organic sales decreased 4.3% from self-inflicted operational challenges. These issues led to margin compression, with gross margin contracting 50 basis points to 32.4% and adjusted operating margin down 140 basis points to 14.6%.

Consequently, Avantor significantly lowered its full-year 2025 guidance, now projecting organic revenue growth of negative 3.5% to negative 2.5% and adjusted EPS of $0.88-$0.92, both below prior estimates. Management initiated a multi-year "Avantor Revival" plan, targeting $400 million in run-rate savings by 2027 through a cost-transformation program and operational improvements.

Despite current execution challenges, management highlighted healthy order intake in bioprocessing, suggesting underlying demand for mission-critical products remains intact. However, operational inefficiencies and supply-chain complexity are currently preventing these strengths from translating into improved financial results, with benefits of the cost program not yet fully impacting the bottom line.

Key Decisions for Investors

• Consider reducing or avoiding exposure to AVTR given the significant Q3 miss, lowered 2025 guidance, and Zacks Strong Sell rating
• Monitor the progress of the multi-year "Avantor Revival" plan, particularly the $400 million cost-transformation program and operational improvements, as execution will be key to future performance
• Evaluate if the current stock price fully discounts the multi-quarter timeline for operational improvements and the potential for continued competitive and execution headwinds